[A25-155] Cemiplimab (cutaneous squamous cell carcinoma, CSCC) – Benefit assessment according to §35a Social Code Book V
Last updated 16.03.2026
Project no.:
A25-155
Commission:
Commission awarded on 15.12.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation; adjuvant treatment
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-155
| Project no. | Title | Status |
|---|---|---|
| A23-36 | Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-37 | Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-97 | Cemiplimab (basal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-98 | Cemiplimab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-60 | Cemiplimab - Benefit assessment according to §35a Social Code Book V | Commission completed |